Poland· PL-100003952
Tysabri
A natalizumab product containing natalizumabum, registered in Poland by Biogen Netherlands B.V.. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Natalizumab is registered in 2 of 19 countries.
Countries holding a registration under ATC L04AA23 (natalizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Natalizumab · ATC L04AA23
2 / 19 countries
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Natalizumabum
- Manufacturer
- Biogen Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- L04AA23
- ATC class
- Natalizumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990084333
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
323 interactions on record for natalizumab.
Graded by severity as the source publishes them — 301 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Natalizumab · interactions on record
323 records
- 301 severe
- 15 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Natalizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTyrukoAbacus Medicine A/S
- CzechiaTYRUKOSandoz GmbH, Kundl
- IrelandTyruko 300 mg concentrate for solution for infusionPolpharma Biologics S.A.
- IcelandTyrukoSandoz GmbH*
- SwedenTyruko 300 mg Koncentrat till infusionsvätska, lösningSandoz GmbH
- BelgiumTyruko 300 mgSandoz
- NorwayTyrukoSandoz GmbH
- SpainTYRUKO 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONSandoz Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tyruko, Tysabri
- Liechtenstein · Tyruko, Tysabri
- Norway · Tyruko, Tysabri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aed4fb55-0834-43db-9b6a-1dda1045d651 GET /v1/drugs/aed4fb55-0834-43db-9b6a-1dda1045d651?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "300 mg",
"packaging": "05909990084333 ¦ Rpz ¦ EU/1/06/346/001 ¦ 28742\n1 fiol. 15 ml",
"substance": "Natalizumabum 300 mg",
"common_name": "Natalizumabum",
"pl_product_id": "100003952",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about natalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.